The 8 most recent market catalysts affecting $LBRX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 3, 2026
Corporate Catalyst
Neutral
Impact 55
LB Pharmaceuticals Appoints Joseph Miller CFO
LB Pharmaceuticals announced the appointment of Joseph Miller as its new Chief Financial Officer. This is a standard corporate governance event, indicating a change in the company'…
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 55
HC Wainwright & Co. Maintains Buy on LB Pharmaceuticals, Raises Price Target to $60
HC Wainwright & Co. analyst Raghuram Selvaraju maintained a 'Buy' rating on LB Pharmaceuticals (LBRX) and raised the price target from $45 to $60. This action indicates increased c…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 65
BMO Capital Maintains Outperform on LB Pharmaceuticals, Raises Price Target to $54
BMO Capital's analyst Malcolm Hoffman has maintained an 'Outperform' rating on LB Pharmaceuticals and raised the price target from $46 to $54. This action signals increased confide…
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 95
LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) Estimate
LB Pharmaceuticals (LBRX) announced Q2 earnings per share of $(1.71), which was a substantial miss compared to the analyst consensus estimate of $(0.80). This 113.75% deviation fro…
Aug 3, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a 'Buy' rating and a $45 price target for LB Pharmaceuticals (LBRX). This action signals that the analyst's investment…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 75
LB Pharmaceuticals Commences ~$150M Offering Of Common Shares, Pre-Funded Warrants
LB Pharmaceuticals announced a private placement to a limited group of institutional investors, selling common stock and pre-funded warrants to raise approximately $150 million. Th…
Jul 22, 2026
Corporate Catalyst
Neutral
Impact 75
LB Pharma Now Expects To Report Topline Results From Pivotal Phase 3 NOVA-2 Clinical Trial Of LB-102 In Patients With Schizophrenia In H1 Of 2027 And To Schedule Pre-NDA Meeting With FDA In H2 Of 2027
LB Pharmaceuticals (LBRX) has announced a significant delay in the expected timeline for its pivotal Phase 3 NOVA-2 clinical trial for LB-102, a drug targeting schizophrenia. Topli…
Jul 21, 2026
Corporate Catalyst
Neutral
Impact 65
BMO Capital Initiates Coverage On LB Pharmaceuticals with Outperform Rating, Announces Price Target of $46
BMO Capital's initiation of coverage on LB Pharmaceuticals with an 'Outperform' rating and a $46 price target is a significant event for the company. Analyst initiations, especiall…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.